Disease Information

General Information of the Disease (ID: DIS00577)

• Name: Severe Acute Respiratory Syndrome coronavirus
• ICD: ICD-11: XN1V8

Type(s) of Resistant Mechanism of This Disease

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Bamlanivimab

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Spike glycoprotein (S) [1]

• Resistant Disease: severe acute respiratory syndrome coronavirus 2 [ICD-11: XN1V8]
• Resistant Drug: Bamlanivimab
• Molecule Alteration: Mutation; .
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: Patient-derived allogeneic stem cell transplant model; Homo sapiens
• Mechanism Description: We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

References

• Ref 1: Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection. Antivir Ther. 2024 Feb;29(1):13596535221097495.